Enhancement of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica by co-treatment with ketoconazole

Veterinary Parasitology

Volumn 177, Issue 3-4, 2011, Pages 305-315

  Devine, C ^a   Brennan, G P ^a   Lanusse, C E ^b   Alvarez, L I ^b   Trudgett, A ^a   Hoey, E ^a   Fairweather, I ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSIDAD NACIONAL DEL CENTRO DE LA PROVINCIA DE BUENOS AIRES   (Argentina)

Author keywords

Fasciola hepatica; Ketoconazole; Liver fluke; Scanning electron microscopy; Triclabendazole resistance

Indexed keywords

KETOCONAZOLE; TRICLABENDAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DISRUPTION; CELL SWELLING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SENSITIVITY; FASCIOLA HEPATICA; FASCIOLIASIS; IN VIVO STUDY; MALE; MONOTHERAPY; NONHUMAN; PARASITE ISOLATION; RAT; SYNCYTIUM; WORM TEGUMENT;

ANIMALS; BENZIMIDAZOLES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FASCIOLA HEPATICA; FASCIOLIASIS; GASTROINTESTINAL DISEASES; KETOCONAZOLE; MALE; MICROSCOPY, ELECTRON, SCANNING; RATS; RATS, SPRAGUE-DAWLEY;

FASCIOLA HEPATICA; RATTUS; RATTUS NORVEGICUS;

EID: 79954608288     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetpar.2010.12.002     Document Type: Article

References (43)

1. Alvarez L.I., Solana H.D., Mottier M.L., Virkel G.L., Fairweather I., Lanusse C.E. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes. Parasitology 2005, 131:501-510.
2. Alvinerie M., Dupuy J., Kiki-Mvouaka S., Sutra J.-F., Lespine A. Ketoconazole increases the plasma levels of ivermectin in sheep. Vet. Parasitol. 2008, 157:117-122.
3. Anderson H.R., Fairweather I. Fasciola hepatica: ultrastructural changes to the tegument of juvenile flukes following incubation in vitro with the deacetylated (amine) metabolite of diamphenethide. Int. J. Parasitol. 1995, 25:319-333.
4. Benchaoui H.A., McKellar Q.A. Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. J. Pharm. Pharmacol. 1996, 48:753-759.
5. Bennett C.E., Hughes D.L., Harness E. Fasciola hepatica: changes in tegument during killing of adult flukes surgically transferred to sensitized rats. Parasite Immunol. 1980, 2:39-55.
6. Boray J.C., Crowfoot P.D., Strong M.B., Allison J.R., Schellenbaum M., Von Orelli M., Sarasin G. Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole. Vet. Rec. 1983, 113:315-317.
7. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitology 2009, 136:183-192.
8. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole. Parasitology 2010, 135:871-880.
9. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol. Res. 2010, 106:1351-1363.
10. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole. Parasitol. Res. 2010, 107:337-353.
11. Devine, C., Brennan, G.P., Lanusse, C.E., Alvarez, L.I., Trudgett, A., Hoey, E.M., Fairweather, I. Piperonyl butoxide enhances triclabendazole action against triclabendazole-resistant Fasciola hepatica. Parasitology, in press, doi:10.1017/S0031182010001125.
12. Fairweather I. Triclabendazole: new skills to unravel an old(ish) enigma. J. Helminthol. 2005, 79:227-234.
13. Fairweather I. Triclabendazole progress report, 2005-2009: an advancement of learning?. J. Helminthol. 2009, 83:139-150.
14. Fairweather I., Anderson H.R., Threadgold L.T. Fasciola hepatica: tegumental changes induced in vitro by the deacetylated (amine) metabolite of diamphenethide. Exp. Parasitol. 1986, 62:336-348.
15. Fairweather I., Threadgold L.T., Hanna R.E.B. Development of Fasciola hepatica in the mammalian host. Fasciolosis 1999, 47-111. CAB International, Wallingford, Oxon, UK. J.P. Dalton (Ed.).
16. Halferty L., Brennan G.P., Hanna R.E.B., Edgar H.W., Meaney M.M., McConville M., Trudgett A., Hoey L., Fairweather I. Tegumental surface changes in juvenile Fasciola hepatica in response to treatment in vivo with triclabendazole. Vet. Parasitol. 2008, 155:49-58.
17. Halferty L., Brennan G.P., Trudgett A., Hoey L., Fairweather I. The relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Vet. Parasitol. 2009, 159:126-138.
18. Hennessy D.R., Lacey E., Steel J.W., Prichard R.K. The kinetics of triclabendazole disposition in sheep. J. Vet. Pharmacol. Ther. 1987, 10:64-72.
19. Keiser J., Utzinger J., Vennerstrom J.L., Dong Y., Brennan G.P., Fairweather I. Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:1219-1222.
20. Lanusse C.E., Prichard R.K. Enhancement of the plasma concentration of albendazole sulfoxide in sheep following coadministration of parenteral netobimin and liver oxidase inhibitors. Res. Vet. Sci. 1991, 51:306-312.
21. Lanusse C.E., Prichard R.K. Effects of methimazole on the kinetics of netobimin metabolites in cattle. Xenobiotica 1992, 22:115-123.
22. Lanusse C.E., Prichard R.K. Methimazole increases the plasma concentrations of the albendazole metabolites of netobimin in sheep. Biopharm. Drug Dispos. 1992, 13:95-103.
23. Lanusse C.E., Prichard R.K. Clinical pharmacokinetics and metabolism of benzimidazole anthelmintics in ruminants. Drug. Metab. Rev. 1993, 25:235-279.
24. Lanusse C.E., Gascon L., Prichard R.K. Methimazole-mediated modulation of netobimin biotransformation in sheep: a pharmacokinetic assessment. J. Vet. Pharmacol. Ther. 1992, 15:267-274.
25. Lanusse C.E., Gascon L.H., Prichard R.K. Influence of the antithyroid compound methimazole on the plasma disposition of fenbendazole and oxfendazole in sheep. Res. Vet. Sci. 1995, 58:222-226.
26. López-García M.L., Torrado S., Torrado S., Martínez A.R., Bolás F. Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. Vet. Parasitol. 1998, 75:209-219.
27. McConville M., Brennan G.P., Flanagan A., Edgar H.W.J., McCoy M., Castillo R., Hernández-Campos A., Fairweather I. Surface and internal tegumental changes in juvenile Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha. Vet. Parasitol. 2008, 153:52-64.
28. McConville M., Brennan G.P., Flanagan A., Edgar H.W.J., Hanna R.E.B., McCoy M., Gordon A.W., Castillo R., Hernández-Campos A., Fairweather I. An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica. Vet. Parasitol. 2009, 162:75-88.
29. McConville M., Brennan G.P., Flanagan A., Hanna R.E.B., Edgar H.W.J., Castillo R., Hernández-Campos A., Fairweather I. Surface changes in adult Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha. Parasitol. Res. 2009, 105:757-767.
30. McKellar Q.A., Gokbulut C., Muzandu K., Benchaoui H. Fenbendazole pharmacokinetics, metabolism, and potentiation in horses. Drug Metab. Dispos. 2002, 30:1230-1239.
31. McKinstry B., Fairweather I., Brennan G.P., Forbes A.B. Fasciola hepatica: tegumental surface alterations following treatment in vivo and in vitro with nitroxynil (Trodax). Parasitol. Res. 2003, 91:251-263.
32. McKinstry B., Brennan G.P., Halferty L., Forbes A.B., Fairweather I. Ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo and in vitro drug treatment with nitroxynil (Trodax). Parasitol. Res. 2007, 101:929-941.
33. Meaney M., Fairweather I., Brennan G.P., McDowell L.S.L., Forbes A.B. Fasciola hepatica: effects of the fasciolicide clorsulon in vitro and in vivo on the tegumental surface, and a comparison of the effects on young- and old-mature flukes. Parasitol. Res. 2003, 91:238-250.
34. Meaney M., Fairweather I., Brennan G.P., Forbes A.B. Transmission electron microscope study of the ultrastructural changes induced in the tegument and gut of Fasciola hepatica following treatment with clorsulon. Parasitol. Res. 2004, 92:232-241.
35. Merino G., Molina A.J., García J.L., Pulido M.M., Prieto J.G., Álvarez A.I. Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. Int. J. Pharmaceut. 2003, 263:123-132.
36. Robinson M.W., Lawson J., Trudgett A., Hoey E.M., Fairweather I. The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol. Res. 2004, 92:205-210.
37. Sánchez S., Small J., Jones D.G., McKellar Q.A. Plasma achiral and chiral pharmacokinetic behavior of intravenous oxfendazole co-administered with piperonyl butoxide in sheep. J. Vet. Pharmacol. Ther. 2002, 25:7-13.
38. Sánchez-Bruni S.F.S., Fusé L.A., Moreno L., Saumell C.A., Álvarez L.I., Fiel C., McKellar Q.A., Lanusse C.E. Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses. Equine Vet. J. 2005, 37:257-262.
39. Stitt A.W., Fairweather I. The effect of the sulphoxide metabolite of triclabendazole ('Fasinex') on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica. Parasitology 1994, 108:555-567.
40. Toner E., Brennan G.P., Hanna R.E.B., Edgar H.W., Fairweather I. Tegumental surface changes in adult Fasciola hepatica in response to treatment in vivo with triclabendazole in the sheep host. Vet. Parasitol. 2010, 172:238-248.
41. Virkel G., Lifschitz A., Sallovitz J., Pis A., Lanusse C. Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep. J. Vet. Pharmacol. Ther. 2006, 29:213-223.
42. Virkel G., Lifschitz A., Sallovitz J., Ballent M., Scarcella S., Lanusse C. Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep. J. Vet. Pharmacol. Ther. 2009, 32:79-86.
43. Walker S.M., McKinstry B., Boray J.C., Brennan G.P., Trudgett A., Hoey E.M., Fletcher H., Fairweather I. Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitol. Res. 2004, 94:427-438.